iBio (IBIO) Stock Price, News & Analysis

Company Overview

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Key Stats

• Today's Range: $1.88 to $1.93
• 50-Day Range: $1.42 to $2.24
• 52-Week Range: $0.56 to $3.82
• Volume: 317,627 shs
• Average Volume: 869,467 shs
• Market Capitalization: $94.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.75
• Consensus Rating: Buy

iBio Stock Analysis - MarketRank™

iBio scored higher than 81% of companies evaluated by MarketBeat, and ranked 17th out of 84 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Buy

Consensus Rating

iBio has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 3 strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

iBio has a consensus price target of $4.75, representing about 150.0% upside from its current price of $1.90.

Amount of Analyst Coverage

iBio has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for iBio are expected to grow in the coming year, from ($0.36) to ($0.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of iBio is -3.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of iBio is -3.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

iBio has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.06% of the float of iBio has been sold short.

Short Interest Ratio / Days to Cover

iBio has a short interest ratio ("days to cover") of 3.56, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in iBio has recently decreased by 0.23%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

iBio does not currently pay a dividend.

Dividend Growth

iBio does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.52

News Sentiment

iBio has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.02 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for iBio this week, compared to 2 articles on an average week.

Search Interest

14 people have searched for IBIO on MarketBeat in the last 30 days. This is an increase of 1,300% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added iBio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 3.8 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of iBio in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $75,085.00 in company stock, which represents 0.0795% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, iBio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $75,085.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

2.75% of the stock of iBio is held by insiders.

Percentage Held by Institutions

7.90% of the stock of iBio is held by institutions.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 5/30/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IBIO
• Previous Symbol: NYSEMKT:IBIO
• CIK: 1420720
• Web: N/A
• Phone: (302) 355-0650
• Fax: 302-356-1173
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for iBio: $4.75
• High Price Target: $7.00
• Low Price Target: $2.00
• Potential Upside/Downside: +150.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.38 million
• Net Margins: N/A
• Pretax Margin: -9,202.00%
• Return on Equity: -53.86%
• Return on Assets: -46.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.88
• Quick Ratio: 11.88

Sales & Book Value

• Annual Sales: $400 thousand
• Price / Sales: 235.98
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.56 per share
• Price / Book: 1.22

Miscellaneous

• Outstanding Shares: 49,680,000
• Free Float: 48,313,000
• Market Cap: $94.39 million
• Optionable: N/A
• Beta: 1.23